Micheletti J Morgan, Hall Brad, Smiley Hayden G, Langston William J
Berkeley Eye Center, Houston, TX, USA.
Sengi, Penniac, NB, Canada.
Clin Ophthalmol. 2025 Jan 29;19:309-316. doi: 10.2147/OPTH.S504090. eCollection 2025.
To determine if visual outcomes with PanOptix are non-inferior to visual outcomes with Synergy.
This was an ambispective, single center, comparative, bilateral, observational study. Patients received bilateral implantation with either PanOptix or Synergy intraocular lenses (IOLs) and were enrolled at least 5 months after surgeries. Patients with postoperative spherical equivalent ± 0.50D and astigmatism ≤ 0.75D in both eyes were enrolled. Postoperatively, patients were tested for binocular uncorrected and distance corrected visual acuities at distance, intermediate (60cm), and near (40cm and 33cm), binocular defocus curve, and were administered questionnaires about quality of vision (QUVID) and spectacle independence (IOLSAT).
A total of 230 subjects completed the study, 153 in the PanOptix group and 77 in the Synergy group. Non-inferiority of visual acuities were confirmed for all testing distances, with and without distance correction in place. No significant differences were observed for the binocular defocus curves (p > 0.05). Severity of starburst, halo, and glare were rated as "None" in 65% (98/150), 38% (58/152), and 48% (72/151) of subjects with the PanOptix Group, compared to 49% (37/76), 38% (29/77), and 55% (42/77) for the Synergy Group, respectively. The percentage of patients "Satisfied" or "Very Satisfied" with their vision was 89% (136/153) in the PanOptix group and 94% (72/77) in the Synergy group.
The results of this study suggest excellent visual acuities at distance, intermediate, and near, high spectacle independence, and high patient satisfaction with both the PanOptix and Synergy IOLs. The incidence of starbursts and blurred vision, as well as visual acuities at extreme near (33 cm), may be higher with the Synergy IOL.
确定PanOptix人工晶状体的视觉效果是否不劣于Synergy人工晶状体的视觉效果。
这是一项回顾性和前瞻性相结合的单中心、对比性、双侧观察性研究。患者接受PanOptix或Synergy人工晶状体的双侧植入，并在手术后至少5个月入组。纳入双眼术后等效球镜度±0.50D且散光≤0.75D的患者。术后，对患者进行远距离、中距离（60cm）和近距离（40cm和33cm）的双眼未矫正和矫正视力测试、双眼散焦曲线测试，并发放关于视觉质量（QUVID）和眼镜依赖程度（IOLSAT）的问卷。
共有230名受试者完成了研究，其中PanOptix组153名，Synergy组77名。在所有测试距离下，无论是否进行距离矫正，均证实了视力的非劣效性。双眼散焦曲线未观察到显著差异（p>0.05）。PanOptix组65%（98/150）、38%（58/152）和48%（72/151）的受试者将星芒、光晕和眩光的严重程度评为“无”，而Synergy组分别为49%（37/76）、38%（29/77）和55%（42/77）。PanOptix组中对视力“满意”或“非常满意”的患者比例为89%（136/153），Synergy组为94%（72/77）。
本研究结果表明，PanOptix和Synergy人工晶状体在远距离、中距离和近距离均具有出色的视力，眼镜依赖程度高，患者满意度高。Synergy人工晶状体的星芒和视物模糊发生率以及极近距离（33cm）的视力可能更高。
